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Edited by Robert BaroukiAbstract We have generated transgenic rabbits that express
the entire human apoA-I/C-III/A-IV gene cluster. As in humans,
h-apoA-I and h-apoC-III were expressed in liver and intestine,
whereas h-apoA-IV mRNA was detected in intestine only.
Transgenic rabbits had signiﬁcantly higher plasma total choles-
terol, HDL-cholesterol and total phospholipid concentrations
than non-transgenic littermates. In contrast to similar transgenic
mice previously generated, which have gross hypertriglyceride-
mia, triglyceride concentrations were only moderately raised in
transgenic rabbits. Plasma and HDL from transgenic rabbits
were more eﬀective than those from controls in promoting
cholesterol eﬄux from cultured hepatoma cells. They had lower
LCAT, lower CETP and higher PLTP activities than non-
transgenic littermates. Cholesterol-feeding produced major in-
creases in plasma lipids. The qualitative response to the diet was
not modiﬁed by cluster expression. Human apoA-I concentration
was halved by cholesterol-feeding, whereas h-apoC-III and h-
apoA-IV concentrations were not signiﬁcantly altered. Choles-
terol eﬄux from hepatoma cells to plasma and HDL was not
altered by the diet. Since lipoprotein metabolism of rabbits
closely resembles that of humans, human apoA-I/C-III/A-IV
transgenic rabbits may provide a reliable model for studies of the
transcriptional regulation of the cluster, and for evaluating the
eﬀects of diﬀerent agents on the expression of the three genes.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The genes coding for human apolipoproteins (apo) A-I, C-
III, and A-IV are tandemly organized in a cluster located on
the long arm of chromosome 11q23-q24 (h-apoA-I/C-III/A-
IV). The tissue-speciﬁc expression of the three genes is
primarily controlled at the level of transcription, which is* Corresponding author. Fax: +33-1-34-65-22-41.
E-mail address: houdebine@jouy.inra.fr (L. Marie Houdebine).
1 These two authors contributed equally to this work.
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.07.041coordinately regulated by positive and negative DNA elements
spread throughout the cluster sequence [1,2].
ApoA-I, apoC-III and apoA-IV make essential contribu-
tions in lipid transport and homeostasis. Mutations in the
cluster gene sequence have major consequences in lipoprotein
remodeling, and have been associated with several dyslipo-
proteinemias and premature coronary artery disease [3].
Much eﬀort has been directed to the study of transgenic
animals expressing the h-apoA-I, h-apoC-III or h-apoA-IV
genes, and these have provided new insights into the function
of each apolipoprotein and the mechanism of atherogenesis [4–
10]. However, none of these models is suitable for analysis of
the coordinated expression of the three genes. For that reason,
we have previously generated transgenic mice expressing the
entire gene cluster h-apoA-I/C-III/A-IV [11].
Lipoprotein metabolism and atherogenesis in rabbits re-
semble their human counterparts more closely than do those in
mice. Rabbits, like humans and unlike mice, express cho-
lesteryl ester transfer protein (CETP), which plays a key role in
lipoprotein remodeling. In addition, in rabbits the concentra-
tion and composition of apoB-containing lipoproteins are
similar to those in humans. Furthermore, in the rabbit hepatic
apoB100 and intestinal apoB48 synthesis pattern resembles
that of humans [12]. Therefore, in the present work we have
generated and characterized transgenic rabbits expressing the
h-apoA-I/C-III/A-IV cluster, and have studied the eﬀects of a
high-cholesterol diet in the animals.2. Materials and methods
2.1. Animals
A transgene containing 8.3 kb of the 50 region of apoA-I, the entire
17-kb h-apoA-I/C-III/A-IV gene cluster, and 7.5 kb of the 30 region of
apoA-IV was micro-injected into fertilized ovocytes from New Zealand
White rabbits. We have previously used the same transgene to produce
h-apoA-I/C-III/A-IV transgenic mice [11]. Three diﬀerent transgenic
lines were established (lines 8, 15 and 23). All procedures involving
animal handling and care were conducted in accordance with the
guidelines of the French Commission de Genie Genetique.
2.2. Cholesterol-feeding experiment
Transgenic rabbits from line 8 and non-transgenic littermates aged 3
months were fed either a high-cholesterol (0.5% w/w) or a chow dietation of European Biochemical Societies.
Fig. 1. Northern blot analysis of human apolipoprotein (apo) A-I,
apoC-III and apoA-IV mRNA in a representative human apoA-I/C-
III/A-IV transgenic rabbit (line 8). Each membrane was hybridized
with two radioactive probes: h-apoA-I, h-apoC-III, or h-apoA-IV, and
18S rRNA. Expression was analyzed in brain, heart, lung, small in-
testine, duodenum, liver, spleen and kidney.
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females.
2.3. Northern blots
Total RNA was extracted from diﬀerent tissues (liver, small intes-
tine, duodenum, spleen, kidney, brain, lung and heart) with RNA-plus
(Q-BIOgene). Northern blot assays were performed with cDNA probes
for each human apolipoprotein as previously reported [11]. Human b-
actin (Clontech) or 18S rRNA probes were used as internal controls to
normalize apolipoprotein signals.
2.4. Apolipoprotein, lipid and lipoprotein analyses
Human apoA-I and apoC-III were quantiﬁed by immunoelectro-
phoresis using speciﬁc polyclonal antibodies (Hydragels SEBIA).
Human apoA-IV was measured by a sandwich ELISA [13]. Rabbit
apolipoproteins did not cross-react. Plasma lipids (total and free
cholesterol, triglycerides and phospholipids) and HDL-cholesterol
were measured colorimetrically (Boehringer Mannheim). To quantify
HDL-cholesterol, apoB-containing lipoproteins were precipitated
with sodium phosphotungstate/magnesium chloride (Boehringer
Mannheim).
Lipoproteins from pooled plasma samples were separated into
density (d) fractions by sequential isopycnic ultracentrifugation as
described [14].
2.5. Cholesterol eﬄux experiments
Cellular cholesterol eﬄux was determined using Fu5AH rat hepa-
toma cells as previously described [15]. The cells were incubated with
either 5% diluted serum or HDL fraction (obtained by ultracentrifu-
gation) at a protein concentration of 50 lg/mL. All eﬄux values pre-
sented are averages of three determinations.
2.6. Enzyme and lipid transfer protein activities
Lecithin:cholesterol acyltransferase (LCAT) activity was deter-
mined by use of the exogenous proteoliposome substrate method [16].
CETP and phospholipid transfer protein (PLTP) activities were
measured using the methods described by Lagrost [17] and Damen
[18], respectively.
2.7. Statistical analyses
Data are expressed as means standard deviation (S.D.). Statistical
analysis was performed with the StatView 4.5 program. Diﬀerences
between groups were analyzed by two-way ANOVA and were con-
sidered to be signiﬁcant if P < 0:05.3. Results
3.1. Characterization of human apoA-I/C-III/A-IV transgenic
rabbits
Human apoA-I/C-III/A-IV expression. Southern blot analy-
ses revealed that the three established transgenic lines (8, 15
and 23) contained the entire h-apoA-I/C-III/A-IV cluster and
its ﬂanking sequences (not shown). In transgenic rabbits from
the three lines, h-apoA-I and h-apoC-III mRNAs were present
in the liver and intestine, whereas h-apoA-IV mRNA was
detected only in the intestine, corresponding to the human
expression pattern. No expression of the human apolipopro-
teins was observed in other tissues that were analyzed. Results
for a representative transgenic line are shown in Fig. 1.
Human apolipoprotein and lipid concentrations. Human
apolipoprotein and lipid concentrations were assayed in 3-
months-old transgenic rabbits from the three established lines.
The lipid proﬁle of each line was compared with that of age-
matched non-transgenic littermates.
The three human apolipoproteins were present in plasma
from all transgenic rabbits (Table 1). Transgenic rabbits had
signiﬁcantly raised plasma lipid concentrations relative to
those in non-transgenic littermates (Table 1). Both totalcholesterol and HDL-cholesterol concentrations were signiﬁ-
cantly greater in transgenic rabbits, but there was no signiﬁ-
cant diﬀerence in the concentration of non HDL-cholesterol.
Phospholipids were also greatly increased. Triglyceride con-
centrations were moderately raised in h-apoA-I/C-III/A-IV
transgenic rabbits relative to control littermates.
3.2. Eﬀects of a high-cholesterol diet
In order to assess the eﬀect of h-apoA-I/C-III/A-IV expres-
sion on lipoprotein metabolism, transgenic rabbits from line 8
and control littermates were fed a high-cholesterol diet for 12
weeks.
Apolipoprotein expression. Human-apoA-I mRNA in liver
and intestine were reduced by approximately 50% in the cho-
lesterol-fed rabbits relative to transgenic rabbits fed the chow
diet. Human apoC-III expression was also reduced in liver of
cholesterol-fed rabbits, but was not aﬀected in the intestine.
Finally, h-apoA-IV mRNA was not signiﬁcantly modiﬁed in
intestine by the diet, while it remained non-detectable in liver
(Table 2).
Human apolipoprotein and lipid concentrations. Human
apoA-I concentration in the plasma of transgenic rabbits was
signiﬁcantly diminished by the high-cholesterol diet. In con-
trast, h-apoC-III and h-apoA-IV concentrations were not
signiﬁcantly altered. Surprisingly, h-apoC-III levels were
modiﬁed in transgenic rabbits after 12-weeks on the chow diet
(compare data from Tables 1 and 3). The high-cholesterol diet
caused major increases in plasma total cholesterol, triglyceride
and phospholipid concentrations in both transgenic and con-
trol rabbits, but the lipid concentrations remained signiﬁcantly
higher in transgenics. Signiﬁcant diﬀerences resulted from both
genetic and diet eﬀects, as well as from the interaction of both
factors. Triglyceride concentrations showed great variability
among the four groups. Furthermore, in accordance with the
Table 3
Plasma lipid and apolipoprotein concentrations (mg/dL) in control and transgenic rabbits from line 8 on chow and cholesterol-rich diets
Diet Total cholesterol Triglycerides Phospholipid ApoA-I ApoC-III ApoA-IV
Control Chow 48 27.1a 18 18.6a 66 18.7a ND ND ND
Cholesterol 1225 291.4b 197 103.5b 543 108.8b ND ND ND
Tg8 Chow 92 35.6c 186 112.8b 197 45.0c 190 47.7a 2.0 0.79a 7 3.0a
Cholesterol 1931 51.1d 921 619.6c 1424 361.3d 116 21.7b 2.5 1.18a 5 2.4a
Two-way Genetic eﬀect <0.0001 0.0003 <0.0001 ND ND ND
ANOVA Diet eﬀect <0.0001 0.0003 <0.0001 ND ND ND
P-values Interaction <0.0001 0,02 <0.0001 ND ND ND
Data are mean S.D., n ¼ 8. ND indicates not determined.
Values in each column with diﬀerent letters diﬀer, P < 0:05.
Table 2
Abundance of apoA-I, apoC-III and apoA-IV liver and intestinal mRNAs in transgenic rabbits from line 8 on chow and cholesterol-rich diets
Organ Diet ApoA-I ApoC-III ApoA-IV
Liver Chow 1.7 0.47 3.5 0.61 ND
Cholesterol 0.9 0.26** 2.2 0.59** ND
Intestine Chow 1.4 0.47 0.9 0.28 1.3 0.38
Cholesterol 0.8 0.16* 1.0 0.25 1.2 0.48
Data are means S.D., n ¼ 8. ND indicates not detected.
Values are reported as arbitrary units normalized to b-actin mRNA levels.
*P < 0:05, **P < 0:01 vs. chow diet fed rabbits.
Table 1
Plasma lipid and human apolipoprotein concentrations (mg/dL) in control and transgenic rabbits
Strain Total cholesterol Triglyceride HDL-C Phospholipid ApoA-I ApoC-III ApoA-IV
Control (n ¼ 69) 50 17.4 42 16.3 30 8.4 84 25.9 ND ND ND
Tg8 (n ¼ 22) 81 20.7* 66 33.2y 56 16.8* 156 37.6* 146 20.3 0.6 0.36 7.5 1.73
Tg15 (n ¼ 19) 66 17.0y 60 27.1y 47 12.0x 116 40.6x 119 19.4 1.1 0.44 5.4 2.09
Tg23 (n ¼ 11) 78 18.5y 52 13.7 49 11.9y 139 37.3x 128 18.5 1.2 0.59 4.9 0.68
Data are means S.D. ND indicates not determined.
* P < 0:0001, x P < 0:01, and y P < 0:05 vs. non-transgenic control rabbits.
296 D. Recalde et al. / FEBS Letters 572 (2004) 294–298observed modiﬁcation of the h-apoC-III concentration on the
same diet (see above), plasma triglyceride concentrations in
transgenic rabbits fed the chow diet changed signiﬁcantly
during the 12-weeks experiment.
Lipid distribution. Plasma lipoproteins were isolated by se-
quential ultracentrifugation from two pools of plasma for each
group of rabbits, and their lipid and apolipoprotein compo-
sitions were analyzed. The eﬀects of the high-cholesterol diet
on lipid distribution were similar in transgenic and control
rabbits. While the high-cholesterol diet greatly raised non-
HDL cholesterol concentration, little change was observed in
HDL-cholesterol. Therefore, the percentage of HDL-choles-
terol in plasma became much lower than during the chow diet
(Fig. 2A). A similar pattern was obtained for the phospholipid
distribution (data not shown). In transgenic rabbits, the high-
cholesterol diet raised triglycerides mainly in very low density
(VLDL) and intermediate density (IDL) lipoproteins, and re-
duced it in HDL particles (Fig. 2B).
LCAT, PLTP and CETP activities. During chow diet feed-
ing, LCAT activity was signiﬁcantly lower in the transgenic
rabbits than in control littermates (21 6.6% vs. 38 13.0%,
P < 0:01). The high-cholesterol diet caused a 10-fold decrease
of LCAT activity in both transgenic and control rabbits
(2 2.8% vs. 3 1.9%, NS). In conformity with this, the per-
centage of cholesteryl ester to total cholesterol was lower in
transgenic than in control rabbits during the chow diet(75 8.8% vs. 95 5.5%), and it diminished during the cho-
lesterol rich diet in both the transgenics and controls
(51 13.6% vs. 68 2.7%). CETP activity was also lower in
transgenic rabbits than in the controls during the chow diet
(10 7.4% vs. 26 7.9%, P < 0:01). The high-cholesterol diet
increased CETP activity in transgenics and controls by 8- and
3-fold, respectively (80 1.6% vs. 82 1.6%, NS).
In contrast, PLTP activity was higher in the transgenic than
in the control animals on a chow diet (2.82 0.29 lmol/mL vs.
1.70 0.44 lmol/mL, P < 0:001). During the high cholesterol
diet, PLTP activity decreased in both groups (1.29 0.30 vs.
0.32 0.10 lmol/mL, P < 0:006).
Cholesterol eﬄux. Independently of the diet, plasma from
transgenic rabbits was more eﬀective than plasma from control
rabbits in promoting cholesterol eﬄux from cultured hepa-
toma cells (Fig. 3). The high-cholesterol diet increased cho-
lesterol eﬄux to control rabbit plasma (P < 0:01), but not to
transgenic rabbit plasma. When we measured the capacity of
the HDL fraction to induce eﬄux of cholesterol, we observed
that it was greater with HDL from transgenic rabbits than with
HDL from control animals. This diﬀerence was greater during
the chow diet (8.32 0.51% vs. 3.44 0.42%, P < 0:001) than
during the high cholesterol diet (4.55 0.68% vs. 2.98 0.27%,
P < 0:01). Interestingly, these values were closely correlated
(r ¼ 0:968, P < 0:0001) with the phospholipid content of the
HDL fractions (122.3 4.16 mg/dL vs. 25.4 5.02 mg/dL for
Fig. 2. Lipid concentrations in lipoproteins of control and human
apoA-I/C-III/A-IV transgenic rabbits from line 8 fed chow or high-
cholesterol diets. Lipoproteins were isolated by sequential preparative
ultracentrifugation of two pools of plasma from each group of rabbits.
Each pool was prepared from 4 rabbits. Lipids were quantiﬁed by
enzymatic methods. (A) Cholesterol. (B) Triglycerides. Dashed bars to
left: control rabbits fed chow diet; open bars: control rabbits fed
cholesterol-rich diet; dashed bars to right: transgenic rabbits fed chow
diet; ﬁlled bars: transgenic rabbits fed cholesterol-rich diet. Values for
each bar correspond to meansS.D.
Fig. 3. Eﬄux of [3H]cholesterol from Fu5AH to plasma from control
(open bars) and human apoA-I/C-III/A-IV transgenic (ﬁlled bars)
rabbits from line 8 fed chow or high-cholesterol diets. Data are from a
representative experiment with triplicate wells. Values are expressed as
meansS.D. Statistically signiﬁcant diﬀerences between control and
transgenic rabbits fed the same diet and between control rabbits fed a
chow or a high-cholesterol diet are indicated in the ﬁgure.
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80.7 11.97 mg/dL vs. 38.9 8.33 mg/dL on the high choles-
terol diet).4. Discussion
The present paper reports the ﬁrst successful production of
rabbits expressing the entire human apoA-I/C-III/A-IV genecluster. The tissue speciﬁc expression of the human apoA-I,
apoC-III and apoA-IV genes in the rabbits was the same as
that in humans. Hence, this new strain of transgenic rabbits
may provide a good model for studies of the transcriptional
regulation of the human cluster.
The eﬀects of expression of the human cluster on plasma
lipoproteins in rabbits diﬀered from those in our human apoA-
I/C-III/A-IV gene cluster transgenic mice [11]. The most
striking diﬀerence was in triglyceride concentrations. While
mice developed gross hypertriglyceridaemia, 3-month old
cluster rabbits showed only a modest rise in plasma triglyce-
rides. This diﬀerence was probably related to their lower hu-
man apoC-III concentrations. Nevertheless, plasma
triglyceride and human apoC-III concentrations were sur-
prisingly increased in 7-month-old transgenic rabbits fed a
chow-diet, although they remained lower than in cluster mice.
Both transgenic species developed an increase in plasma HDL-
cholesterol. However, while transgenic mice showed a major
rise in non-HDL-cholesterol, this was not signiﬁcantly modi-
ﬁed in transgenic rabbits.
As would be expected, cholesterol-feeding increased plasma
lipid concentrations in both transgenic and non-transgenic
rabbits. Lipid levels remained higher in the transgenics than in
the non-transgenics throughout. The changes in the distribu-
tions of lipids among the major density factions of lipoproteins
in both groups were consistent with an accumulation of cir-
culating chylomicron remnants. Thus, cluster expression ap-
peared to have little eﬀect on the qualitative nature of the
response to the diet.
Cholesterol-feeding had no eﬀects on the expression levels of
the human apoC-III and apoA-IV genes in small intestine, but
reduced those of human apoA-I in liver and intestine and of
human apoC-III in liver. The decrease in apoA-I expression
was accompanied by a reduction of plasma apoA-I concen-
tration, while concentrations of human apoC-III and human
apoA-IV were unchanged. The failure of apo human C-III to
decrease despite a reduction of human apoC-III expression in
liver during cholesterol-feeding may be attributable to the fact
that the fractional rate of catabolism of C apolipoproteins has
been shown to be a function of the eﬃciency of clearance of
triglyceride-rich lipoproteins and their remnants [19], the
mechanisms for which may have been saturated in the trans-
genics during cholesterol-feeding. In cluster transgenic mice,
feeding a high fat-high cholesterol diet resulted in an increase
in the expression of the three human apolipoprotein genes in
intestine and a decrease in the expression of human apoA-I
gene in liver. The plasma concentrations of the three human
apolipoproteins were signiﬁcantly greater in transgenic mice
fed the atherogenic diet than in chow fed mice [20]. Although
we do not have a clear explanation for this discrepancy be-
tween cluster rabbit and mouse models, there are probably
diﬀerences between the properties of mouse and rabbit tran-
scriptional factors involved in the gene cluster transcription,
leading to modiﬁed aﬃnities for the human gene cluster reg-
ulatory sequences. Furthermore, diﬀerences in the composi-
tions of the diets employed in each study may also have
contributed to the diﬀerent apolipoprotein expression levels.
On the chow diet transgenic rabbits had lower LCAT and
CETP activities, and higher PLTP activities, than their non-
transgenic littermates. During cholesterol-feeding, qualita-
tively similar changes were observed in all three measurements
in transgenics and non-transgenics, LCAT and PLTP activities
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these eﬀects cannot be determined from the present data.
Preliminary experiments performed with groups of 8 animals
demonstrated that the high cholesterol diet caused the devel-
opment of extensive aortic atherosclerosis in both transgenic
and control rabbits (data not shown). No signiﬁcant diﬀerence
was found between the two groups of rabbits in the total
surface area of the lesions. However, as the extent of athero-
sclerosis varied greatly between individual animals of each
group, a larger sample size will be needed to resolve this issue.
Although cholesterol eﬄux from cultured hepatoma cells to
plasma and isolated HDLs was greater when transgenic sam-
ples were used, cholesterol-feeding increased these values only
in the controls. However, cholesterol eﬄux from Fu5AH cells
is a reliable guide only to cholesterol eﬄux stimulated by SR-
BI, and further analyses should be performed with J774 cells
stimulated by cAMP in order to provide a better indication of
the transfer of cholesterol from the ABCA1 receptors [21].
In summary, we have developed the ﬁrst strain of rabbits
expressing the entire human apoA-I/C-III/A-IV gene cluster.
Although further work will be needed to characterize the an-
imals in greater detail, our results thus far suggest that they
may provide a good model for future work on the transcrip-
tional regulation of the human cluster, and for evaluating the
eﬀects of drugs, hormones and other agents on the expression
of the three genes.
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